Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Michaelis

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Hematology. American Society of Hematology. Education Program|December 4, 2018
Cytotoxic therapy in acute myeloid leukemia: not quite dead yetLaura C Michaelis
Best Practice & Research. Clinical Haematology|April 1, 2019
PrefaceLaura C Michaelis
Blood|January 5, 2019
Venetoclax in AML: aiming for "just right"Laura C Michaelis
Blood|March 13, 2020
BCL-2 inhibition and AML: can we best Darwin?Laura C Michaelis
Best Practice & Research. Clinical Haematology|December 6, 2021
Is there an optimal adjunct therapy to traditional cytotoxic induction?Laura C Michaelis
Haematologica|January 2, 2017
Risk stratification in myelofibrosis: the quest for simplificationLaura C Michaelis
Blood|September 2, 2021
The next wave: immunizing the immunosuppressedLaura C Michaelis
Current Hematologic Malignancy Reports|September 28, 2021
Avapritinib in the Treatment of Systemic Mastocytosis: an UpdateSamantha Below, Laura C Michaelis
Current Opinion in Hematology|January 21, 2015
Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014Laura C Michaelis, Harry P Erba
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialtiesLaura C Michaelis, Mark J Ratain
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Hematology. American Society of Hematology. Education Program|December 4, 2018
Cytotoxic therapy in acute myeloid leukemia: not quite dead yetLaura C Michaelis
Best Practice & Research. Clinical Haematology|April 1, 2019
PrefaceLaura C Michaelis
Blood|January 5, 2019
Venetoclax in AML: aiming for "just right"Laura C Michaelis
Blood|March 13, 2020
BCL-2 inhibition and AML: can we best Darwin?Laura C Michaelis
Best Practice & Research. Clinical Haematology|December 6, 2021
Is there an optimal adjunct therapy to traditional cytotoxic induction?Laura C Michaelis
Haematologica|January 2, 2017
Risk stratification in myelofibrosis: the quest for simplificationLaura C Michaelis
Blood|September 2, 2021
The next wave: immunizing the immunosuppressedLaura C Michaelis
Current Hematologic Malignancy Reports|September 28, 2021
Avapritinib in the Treatment of Systemic Mastocytosis: an UpdateSamantha Below, Laura C Michaelis
Current Opinion in Hematology|January 21, 2015
Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014Laura C Michaelis, Harry P Erba
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialtiesLaura C Michaelis, Mark J Ratain
Pageof 6